{"symbol":"PFE","fiscalQuarter":"Q1-2026","reportDate":"2026-05-05","reportTime":"BMO","status":"reported","company":{"name":"Pfizer Inc.","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/PFE/earnings/Q1-2026","estimates":{"consensusEps":0.7232,"consensusRevenue":13805.62,"epsLow":0.56,"epsHigh":0.81,"whisperEps":null,"numAnalysts":null},"preBrief":{"companySnapshot":"Pfizer Inc. is a leading pharmaceutical company known for developing and manufacturing medicines and vaccines. With a market cap of $150 billion, it plays a crucial role in the health care sector, especially in the wake of the COVID-19 pandemic and ongoing health challenges.","keyMetrics":[{"name":"EPS","why":"Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.","consensus":"$0.72"},{"name":"Revenue","why":"Revenue figures provide insight into the company's sales performance and market demand for its products.","consensus":"$13.8B"}],"lastQuarterRecap":{"summary":"In Q4 2025, Pfizer reported an EPS of $0.66, exceeding expectations by 16.81%. However, the stock fell 3.34% the following day, indicating market caution despite the earnings beat.","promises":[]},"wallStreetExpectations":{"summary":"Analysts expect Pfizer to report solid earnings, with a consensus EPS of $0.72 and revenue of $13.8 billion. The market is closely watching how the company navigates post-COVID dynamics.","bullCase":"If Pfizer exceeds EPS expectations, it could signal strong demand for its products and a recovery in its core business, potentially boosting investor confidence.","bearCase":"Conversely, if the company misses earnings expectations or provides weak guidance, it could raise concerns about its growth trajectory and market position."},"optionsSignal":{"impliedMove":"4.2%","context":"The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement."},"earningsTrackRecord":[{"quarter":"Q4-2025","epsSurprise":"+16.81%","reaction":"-3.34%"},{"quarter":"Q3-2025","epsSurprise":"+32.22%","reaction":"-1.46%"},{"quarter":"Q2-2025","epsSurprise":"+36.36%","reaction":"+5.18%"},{"quarter":"Q1-2025","epsSurprise":"+43.75%","reaction":"+3.21%"},{"quarter":"Q4-2024","epsSurprise":"+30.98%","reaction":"-1.26%"}],"pivotalQuestions":[{"question":"Will Pfizer's EPS exceed the consensus estimate of $0.72?","whyItMatters":"A beat on EPS could indicate stronger-than-expected demand for its products and boost investor confidence."},{"question":"What guidance will management provide regarding future revenue growth?","whyItMatters":"Future revenue guidance is crucial for assessing the company's growth trajectory and market outlook."}],"thesisBreakLevels":{"bullTrigger":"An EPS of $0.75 or higher would confirm strong demand and positive market sentiment.","bearTrigger":"An EPS below $0.68 would raise concerns about the company's growth and market position.","context":"This quarter's performance is critical as it reflects Pfizer's ability to sustain growth post-COVID and adapt to changing market conditions."},"scenarioPlaybook":{"beatAndRaise":"If Pfizer beats expectations, history suggests the stock could rise by around 1.15%, confirming a positive outlook.","inLineCautious":"If results are in line with expectations, the stock may see muted movement as investors await further guidance.","miss":"If Pfizer misses earnings expectations, history suggests a potential decline of about 3.01%, raising concerns about its growth."},"whatTheStreetIsMissing":{"thesis":"The Street may underestimate the impact of new product launches and ongoing demand for vaccines, which could drive stronger revenue than expected.","supportingPoints":["Pfizer has consistently beaten EPS estimates in recent quarters, indicating strong operational performance.","The options market is pricing a 4.2% move, suggesting expectations of volatility that may not align with actual performance."],"riskToConsensus":"If new product sales significantly exceed expectations, it could challenge the current consensus view."},"whatToListenFor":["Any commentary on vaccine demand and sales trends.","Updates on new product launches and their expected impact on revenue.","Management's outlook on market conditions and competitive landscape.","Insights into cost management and operational efficiency.","Guidance on future earnings and revenue expectations."],"metaDescription":"Pfizer (PFE) reports Q1 2026 earnings May 5. Analysts expect $0.72 EPS on $13.8B revenue. Here's what to watch."},"postBrief":{"headline":"Pfizer Beats on EPS, Stock Up 0.57%","keyNumbers":[{"metric":"EPS","actual":"$0.75","expected":"$0.72","surprise":"+5.63%"},{"metric":"Revenue","actual":"N/A","expected":"$13.8B","surprise":"N/A"}],"managementCommentary":{"tone":"Unknown","keyQuotes":[],"summary":"No transcript is on record for the earnings call, so analysis is based solely on numerical results."},"guidanceChanges":{"summary":"No forward guidance data is available for this quarter.","changes":[]},"whatItMeans":"Pfizer's earnings report shows a positive surprise in EPS, which likely contributed to the stock's modest increase of 0.57%. However, the lack of revenue data and management commentary leaves some uncertainty about the company's overall performance and future outlook.","metaDescription":"Pfizer Inc. (PFE) Q1 2026 earnings: EPS beat by 5.63%, revenue data not available. Stock up 0.57%. Full breakdown."}}